Director Disclosure Update
Disclosure that Chairman Martin Gouldstone is a director of Oncimmune Holdings PLC, which announced intention to appoint administrators.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, issues the following disclosure in relation to Martin Gouldstone, Chairman of the Company pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Oncimmune Holdings PLC, a company which Martin Gouldstone is a Director, recently announced its intention to appoint administrators.
There is nothing further to disclose in respect of Schedule 2(g) of the AIM Rules for Companies.
The Directors of the Company take responsibility for this announcement.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/oPB60P |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0025 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 7186 9000 |
| V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.